Research Index
B7-33 Research Index
PSI surfaces 50 peer-reviewed studies on B7-33, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Spontaneous Splenic Rupture in a Patient With Recent Use of Performance-Enhancing Compounds: A Case Report and Literature Review.
Jaffry K, Shah J, Naqash N
Cureus·2026·Human·PubMed →
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Tewari K, Liu TP, Im C et al.
Am J Sports Med·2026·Animal·PubMed →
Acute stress suppresses hunger-driven food seeking through PVN activation: Reversal by anxiolytic drug and ghrelin receptor agonist, with anxiolytic-like effects of refeeding.
Tojo R, Tashiro M, Takahashi H et al.
Neurosci Res·2026·Animal·Anxiety & Mood·PubMed →
Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.
Kintz P, Gheddar L
Clin Chim Acta·2026·Animal·PubMed →
Hepatotoxicity induced by MK-677.
Cobani E, Amin MS, Hasso M et al.
BMJ Case Rep·2025·Animal·PubMed →
Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use.
Chong S, Woolnough CA, Koyyalamudi SR et al.
JCEM Case Rep·2024·Animal·PubMed →
Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration.
Viljanto M, Cutler C, Taylor P et al.
Drug Test Anal·2023·Animal·GH Activity·PubMed →
Skin Acceleration Levels Estimated by a Neck-surface Accelerometer during Phonation Are Affected by The Mechanical Properties of The Anterior Cervical Skin.
Umatani M, Ogawa M, Hosokawa K et al.
J Voice·2023·Animal·PubMed →
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
Cardaci TD, Machek SB, Wilburn DT et al.
Exp Physiol·2022·Human·Muscle Recovery·PubMed →
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.
Philip M, Karakka Kal AK, Subhahar MB et al.
Rapid Commun Mass Spectrom·2022·Animal·GH Activity·PubMed →
Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration.
Cutler C, Viljanto M, Taylor P et al.
Drug Test Anal·2022·Animal·GH Activity·PubMed →
Neural networks for computing and denoising the continuous nonlinear Fourier spectrum in focusing nonlinear Schrödinger equation.
Sedov EV, Freire PJ, Seredin VV et al.
Sci Rep·2021·Animal·PubMed →
Development and validation of SARMs and metabolic modulators screening in hair using UHPLC-MS/MS: Application to a doping case and first identification of S23 in authentic human hair.
Gheddar L, Raul JS, Kintz P
J Chromatogr B Analyt Technol Biomed Life Sci·2021·Animal·PubMed →
Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.
Philip M, Karakka Kal AK, Subhahar MB et al.
Rapid Commun Mass Spectrom·2021·Animal·PubMed →
Role of Satb1 and Satb2 Transcription Factors in the Glutamate Receptors Expression and Ca(2+) Signaling in the Cortical Neurons In Vitro.
Turovsky EA, Turovskaya MV, Fedotova EI et al.
Int J Mol Sci·2021·Animal·PubMed →
Development and validation of liquid chromatography-tandem mass spectrometry method for screening six selective androgen receptor modulators in dietary supplements.
Lee JH, Han JH, Jung EJ et al.
Food Addit Contam Part A Chem Anal Control Expo Risk Assess·2021·Animal·PubMed →
Brain and kidney GHS-R1a underexpression is associated with changes in renal function and hemodynamics during neurogenic hypertension.
Sales da Silva E, Ferreira PM, Castro CH et al.
Mol Cell Endocrinol·2020·Animal·PubMed →
MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology.
Tian J, Wang T, Wang Q et al.
J Alzheimers Dis·2019·Animal·PubMed →
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.
Campbell GA, Patrie JT, Gaylinn BD et al.
Nephrol Dial Transplant·2018·Human·GH Activity·PubMed →
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
Lee J, Kwon A, Chae HW et al.
Yonsei Med J·2018·Animal·GH Activity·PubMed →
MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease.
Jeong YO, Shin SJ, Park JY et al.
Int J Mol Sci·2018·Animal·Neuroprotection·PubMed →
Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory.
Harmatz ES, Stone L, Lim SH et al.
Biol Psychiatry·2017·Animal·Cognitive Enhancement, Anxiety & Mood·PubMed →
Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats.
Patel K, Joharapurkar A, Dhanesha N et al.
Drug Res (Stuttg)·2014·Animal·Appetite Regulation, Glycemic Control, Liver Protection·PubMed →
Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor.
Schellekens H, McNamara O, Dinan TG et al.
J Pharm Pharmacol·2013·Animal·Neuroprotection·PubMed →
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Adunsky A, Chandler J, Heyden N et al.
Arch Gerontol Geriatr·2011·Human·PubMed →
Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor.
Bennett KA, Langmead CJ, Wise A et al.
Mol Pharmacol·2009·Animal·GH Activity·PubMed →
Anabolic interventions in ESRD: light at the end of the tunnel?
Hakim RM, Ikizler TA
Am J Kidney Dis·2009·Animal·PubMed →
Rejuvenation in older adults receiving oral ghrelin.
Webster J
Ann Intern Med·2009·Animal·Appetite Regulation, Glycemic Control, GH Activity, Muscle Recovery·PubMed →
Rejuvenation in older adults receiving oral ghrelin.
Gaugg M
Ann Intern Med ·2009·Animal·PubMed →
Rejuvenation in older adults receiving oral ghrelin.
Rafael H
Ann Intern Med·2009·Animal·PubMed →
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ, Ryan JM, van Dyck CH et al.
Neurology·2008·Human·GH Activity·PubMed →
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R, Pezzoli SS, Oliveri MC et al.
Ann Intern Med·2008·Human·PubMed →
Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.
Ann Intern Med·2008·Human·PubMed →
Impurity profile tracking for active pharmaceutical ingredients: case reports.
Zhou L, Mao B, Reamer R et al.
J Pharm Biomed Anal·2007·Human·GH Activity·PubMed →
The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.
Bach MA, Rockwood K, Zetterberg C et al.
J Am Geriatr Soc·2004·Human·GH Activity·PubMed →
The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.
Svensson J, Boguszewski CL, Shibata F et al.
Growth Horm IGF Res·2003·Human·Weight Loss, GH Activity·PubMed →
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E, Cassorla F, Tiulpakov AN et al.
Clin Pharmacol Ther·2001·Human·GH Activity·PubMed →
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG, Weiss S, McClung M et al.
J Clin Endocrinol Metab·2001·Human·Bone Healing, Tissue Remodeling, GH Activity·PubMed →
Endocrine and non-endocrine activities of growth hormone secretagogues in humans.
Ghigo E, Arvat E, Broglio F et al.
Horm Res·1999·Human·GH Activity·PubMed →
Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
Svensson J, Carlsson B, Carlsson LM et al.
Clin Endocrinol (Oxf)·1999·Human·GH Activity, Weight Loss·PubMed →
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG, Bach MA, Plotkin D et al.
J Bone Miner Res·1999·Human·Bone Healing, Tissue Remodeling, GH Activity·PubMed →
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
Svensson J, Jansson JO, Ottosson M et al.
J Clin Endocrinol Metab·1999·Human·Weight Loss, GH Activity·PubMed →
Growth hormone secretagogues: mechanism of action and use in aging.
Fuh VL, Bach MA
Growth Horm IGF Res·1998·Human·Longevity, GH Activity·PubMed →
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J, Ohlsson C, Jansson JO et al.
J Bone Miner Res·1998·Human·Tissue Remodeling, Weight Loss·PubMed →
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J, Lönn L, Jansson JO et al.
J Clin Endocrinol Metab·1998·Human·Weight Loss, GH Activity·PubMed →
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG, Plunkett LM, Gertz BJ et al.
J Clin Endocrinol Metab·1998·Human·GH Activity·PubMed →
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Copinschi G, Leproult R, Van Onderbergen A et al.
Neuroendocrinology·1997·Human·GH Activity, Sleep·PubMed →
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM, Pescovitz OH, Murphy G et al.
J Clin Endocrinol Metab·1997·Human·Glycemic Control, GH Activity·PubMed →
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM, Bach MA, Van Cauter E et al.
J Clin Endocrinol Metab·1996·Human·Glycemic Control, GH Activity·PubMed →
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M et al.
J Clin Endocrinol Metab·1996·Human·PubMed →